Services
Novel drug discovery solutions based on human cells
As a human cell biology company SCI has developed a series of novel technologies and solutions to be accessed through contract research agreements and research partnerships including risk sharing. SCI's philosophy is to develop in vitro applications that model as closely as possible to the human in vivo (disease) physiology. SCI has developed two core technologies: the C3A human liver cell-line and the human pluripotent stem cell platform, PluriCellsTM that form the basis of SCI's current offerings.
